CReATe Podcast

CReATe Author Series Ep. 16 - Dr. Johnathan Cooper-Knock on Exercise and ALS

Dr. Johnathan Cooper-Knock is a neurologist and clinical lecturer at the University of Sheffield.  His research focuses on genetic causes of ALS.  Here he discusses his recent publication “Extreme exercise in males is linked to mTOR signalling and onset of amyotrophic lateral sclerosis”.

ALS Untangled Series Ep. 61 - Zinc

Here we review Zinc supplements as a treatment for ALS.  These are inexpensive, reasonably safe at certain doses, and are easy to acquire.  They have plausible mechanisms by which they could slow ALS progression.  However, the data from people living with ALS is not very convincing yet.

CReATe Author Series Ep. 15 - Drs. Terry Heiman-Patterson and Michael Benatar on Clinical Guidance for ALS/FTD at-risk carriers

Dr. Terry Heiman-Patterson is a neurologist and professor at Temple University and the director of the Center for Neurodegenerative Disorders and the MDA/ALS Center of Hope.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  In this podcast they will be discussing their recent publication “Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD”.

CReATe Author Series Ep. 14 - Drs. Ruben van Eijk and Michael Benatar on Phase 2 Trials and ALS

Dr. Ruben van Eijk is an associate professor in the Department of Neurology at the University Medical Center Utrecht in the Netherlands as well as a statistical consultant and medical statistician for the clinical trial methodology group at the Julius Center also in Utrecht.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  They will be discussing their recent publication “Rethinking phase 2 trials in amyotrophic lateral sclerosis”.

CReATe Author Series Ep. 13 - Dr. Benatar on Prognostic Markers and ALS

Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  Here he discusses the recent publication “Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis”.